Maviret
(glecaprevir/pibrentasvir) AbbVie

Composition:

• Available in film-coated tablet with each contains 100 mg glecaprevir and 40 mg pibrentasvir

Indication:

• Indicated for treatment of chronic hepatitis C virus (HCV) infection in adults and in adolescents aged 12 to <18 years

• A new 8-week indication for treatment-naïve, compensated cirrhotic genotype 1, 2, 4, 5 or 6 HCV patients

Drug information including formulation, indication, administration and/or presentation updated, registered or launched in Hong Kong within one year prior to the date written is regarded as new in The Pace.

The information in The Pace is provided as a courtesy service to our readers and is intended for medical professional reference only. Please peruse the latest local prescription information prior to prescription.